A Phase 2, Multicenter, Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec in Subjects With Unresected, Stage IIIB to IVM1c Melanoma

Trial Profile

A Phase 2, Multicenter, Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec in Subjects With Unresected, Stage IIIB to IVM1c Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Talimogene laherparepvec (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacogenomic; Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 07 Feb 2018 Planned End Date changed from 28 Feb 2018 to 28 Aug 2018.
    • 13 Dec 2017 Planned End Date changed from 29 Dec 2017 to 28 Feb 2018.
    • 06 May 2017 Planned End Date changed from 1 Jun 2017 to 29 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top